[{"id":"2e65ab02-5455-476f-a9fc-8810d776844a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01386385","created_at":"2021-01-19T08:29:02.253Z","updated_at":"2025-02-25T16:36:10.447Z","phase":"Phase 1/2","brief_title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01386385","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ERCC1 • XRCC1","pipe":" | ","alterations":" ERCC1 expression","tags":["ERCC1 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/20/2011","start_date":" 06/20/2011","primary_txt":" Primary completion: 05/26/2019","primary_completion_date":" 05/26/2019","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"49fd164b-4fd1-4bd8-932f-08c45dda5bd8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02128906","created_at":"2021-01-18T09:52:10.167Z","updated_at":"2024-07-02T16:35:15.614Z","phase":"Phase 2","brief_title":"Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design","source_id_and_acronym":"NCT02128906","lead_sponsor":"Christopher Wilke","biomarkers":" ERCC1","pipe":" | ","alterations":" ERCC1 expression","tags":["ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • docetaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/23/2013","start_date":" 12/23/2013","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-03-08"},{"id":"a6714b7e-8c09-40c6-82d5-27418f5ba30c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00059930","created_at":"2021-01-18T00:07:52.504Z","updated_at":"2024-07-02T16:35:44.034Z","phase":"Phase 1","brief_title":"Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer","source_id_and_acronym":"NCT00059930","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ERCC1 • TYMS","pipe":"","alterations":" ","tags":["ERCC1 • TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • dexamethasone • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 01/01/2003","start_date":" 01/01/2003","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-07-04"},{"id":"2f454d62-b561-48df-9aa8-c95f396adca9","acronym":"VOLFI","url":"https://clinicaltrials.gov/study/NCT01328171","created_at":"2021-01-18T05:24:48.418Z","updated_at":"2024-07-02T16:35:45.737Z","phase":"Phase 2","brief_title":"FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)","source_id_and_acronym":"NCT01328171 - VOLFI","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" EGFR • KRAS • PIK3CA • NRAS • PTEN • ERCC1 • RAS • MTHFR","pipe":" | ","alterations":" EGFR mutation • PIK3CA mutation • KRAS wild-type • RAS wild-type • EGFR exon 18 mutation • KRAS exon 2 mutation • EGFR mutation + PIK3CA mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["EGFR • KRAS • PIK3CA • NRAS • PTEN • ERCC1 • RAS • MTHFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PIK3CA mutation • KRAS wild-type • RAS wild-type • EGFR exon 18 mutation • KRAS exon 2 mutation • EGFR mutation + PIK3CA mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2023-06-14"},{"id":"197da2b8-464a-430c-a915-acaaae8ac86a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05832593","created_at":"2023-04-27T14:04:59.039Z","updated_at":"2024-07-02T16:35:49.443Z","phase":"","brief_title":"Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.","source_id_and_acronym":"NCT05832593","lead_sponsor":"Assiut University","biomarkers":" ERCC1","pipe":" | ","alterations":" ERCC1 expression","tags":["ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-04-27"},{"id":"9af23f79-563e-457b-a6af-bde48f421a1e","acronym":"TROG 12.01","url":"https://clinicaltrials.gov/study/NCT01855451","created_at":"2021-02-09T21:52:29.004Z","updated_at":"2025-02-25T16:13:10.235Z","phase":"Phase 3","brief_title":"Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma","source_id_and_acronym":"NCT01855451 - TROG 12.01","lead_sponsor":"Trans Tasman Radiation Oncology Group","biomarkers":" EGFR • ERCC1 • HGF","pipe":"","alterations":" ","tags":["EGFR • ERCC1 • HGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 189","initiation":"Initiation: 06/03/2013","start_date":" 06/03/2013","primary_txt":" Primary completion: 04/30/2020","primary_completion_date":" 04/30/2020","study_txt":" Completion: 08/23/2023","study_completion_date":" 08/23/2023","last_update_posted":"2022-11-18"},{"id":"42fec90d-1616-4bcb-ba10-1468cd201d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05568212","created_at":"2022-10-05T12:56:03.628Z","updated_at":"2024-07-02T16:36:02.981Z","phase":"Phase 2","brief_title":"Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab","source_id_and_acronym":"NCT05568212","lead_sponsor":"Fondazione Ricerca Traslazionale","biomarkers":" TP53 • TMB • BRCA1 • STK11 • KEAP1 • ERCC1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • TP53 expression","tags":["TP53 • TMB • BRCA1 • STK11 • KEAP1 • ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 05/02/2022","start_date":" 05/02/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-10-05"},{"id":"a432a555-c2f8-43ba-befa-5a91db04db5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02535325","created_at":"2021-01-18T12:15:42.112Z","updated_at":"2025-02-25T16:30:42.064Z","phase":"Phase 1","brief_title":"Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02535325","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ERCC1 • NKX2-1","pipe":"","alterations":" ","tags":["ERCC1 • NKX2-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • Pemfexy (pemetrexed) • methoxyamine (TRC102)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 09/30/2015","start_date":" 09/30/2015","primary_txt":" Primary completion: 02/27/2020","primary_completion_date":" 02/27/2020","study_txt":" Completion: 06/14/2022","study_completion_date":" 06/14/2022","last_update_posted":"2022-06-30"},{"id":"2df64dea-ca8e-48a0-be26-620e391d4447","acronym":"","url":"https://clinicaltrials.gov/study/NCT01003964","created_at":"2021-01-19T08:28:56.147Z","updated_at":"2024-07-02T16:36:13.138Z","phase":"Phase 2","brief_title":"Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV","source_id_and_acronym":"NCT01003964","lead_sponsor":"National Cancer Center, Korea","biomarkers":" ERCC1","pipe":"","alterations":" ","tags":["ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • docetaxel • pemetrexed • irinotecan"],"overall_status":"Completed","enrollment":" Enrollment 289","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 06/01/2015","study_completion_date":" 06/01/2015","last_update_posted":"2022-04-12"},{"id":"419a98b5-d2bf-415b-9307-4fc2b382b434","acronym":"TOMAS","url":"https://clinicaltrials.gov/study/NCT02398058","created_at":"2021-04-14T18:53:45.928Z","updated_at":"2025-02-25T15:06:31.322Z","phase":"Phase 1","brief_title":"Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)","source_id_and_acronym":"NCT02398058 - TOMAS","lead_sponsor":"Italian Sarcoma Group","biomarkers":" BRCA1 • ERCC1 • ERCC2 • PARP1 • TP53BP1","pipe":"","alterations":" ","tags":["BRCA1 • ERCC1 • ERCC2 • PARP1 • TP53BP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/20/2014","start_date":" 07/20/2014","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2021-04-14"},{"id":"0ea0e767-8053-4eed-bc9d-21ce24720824","acronym":"PSPM","url":"https://clinicaltrials.gov/study/NCT04160143","created_at":"2021-02-25T18:57:00.986Z","updated_at":"2024-07-02T16:36:34.073Z","phase":"","brief_title":"Post SBRT Pulmonary Metastasectomy (PSPM) Trial","source_id_and_acronym":"NCT04160143 - PSPM","lead_sponsor":"McMaster University","biomarkers":" EGFR • HER-2 • ERCC1 • EPCAM","pipe":"","alterations":" ","tags":["EGFR • HER-2 • ERCC1 • EPCAM"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 07/14/2020","start_date":" 07/14/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2021-02-25"},{"id":"2977bf0f-90bd-4363-8514-42ec7a8c4a41","acronym":"","url":"https://clinicaltrials.gov/study/NCT01703390","created_at":"2021-01-18T07:24:40.417Z","updated_at":"2025-02-25T16:02:44.177Z","phase":"Phase 2","brief_title":"Biomarker Directed Treatment in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01703390","lead_sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","biomarkers":" KRAS • ERCC1","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS • ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 12/04/2012","start_date":" 12/04/2012","primary_txt":" Primary completion: 02/23/2018","primary_completion_date":" 02/23/2018","study_txt":" Completion: 07/03/2020","study_completion_date":" 07/03/2020","last_update_posted":"2020-12-21"},{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"},{"id":"b9f525bf-6e6a-45c6-9db7-7591314b5ffe","acronym":"","url":"https://clinicaltrials.gov/study/NCT00846482","created_at":"2021-01-18T03:13:19.140Z","updated_at":"2024-07-02T16:36:41.015Z","phase":"","brief_title":"Exploratory Study Of The ERCC-1 Gene","source_id_and_acronym":"NCT00846482","lead_sponsor":"Albert Einstein College of Medicine","biomarkers":" ERCC1","pipe":"","alterations":" ","tags":["ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 02/01/2008","start_date":" 02/01/2008","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2020-09-16"},{"id":"4b22131b-479c-418d-9460-87ca3133481d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792701","created_at":"2021-01-18T03:00:30.679Z","updated_at":"2024-07-02T16:36:49.078Z","phase":"Phase 2","brief_title":"S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00792701","lead_sponsor":"Southwest Oncology Group","biomarkers":" ERCC1 • RRM1","pipe":" | ","alterations":" ERCC1 expression • RRM1 expression","tags":["ERCC1 • RRM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression • RRM1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 11/01/2008","start_date":" 11/01/2008","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2020-03-06"},{"id":"01034882-ff09-4402-95a9-db47dc9eb1f2","acronym":"OPHELIA","url":"https://clinicaltrials.gov/study/NCT02882308","created_at":"2021-01-18T14:08:53.097Z","updated_at":"2025-02-25T15:07:14.796Z","phase":"Phase 2","brief_title":"Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.","source_id_and_acronym":"NCT02882308 - OPHELIA","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" PD-L1 • BRCA1 • BRCA2 • ERCC1 • ERCC2 • RAD51C • GSTP1 • PARP1 • XRCC1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • BRCA1 • BRCA2 • ERCC1 • ERCC2 • RAD51C • GSTP1 • PARP1 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin • Imfinzi (durvalumab)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 10/20/2016","start_date":" 10/20/2016","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 01/10/2020","study_completion_date":" 01/10/2020","last_update_posted":"2020-02-07"},{"id":"282ad5ed-28a5-4fcf-8a9b-672046063b64","acronym":"","url":"https://clinicaltrials.gov/study/NCT01059552","created_at":"2021-01-18T04:10:21.319Z","updated_at":"2024-07-02T16:36:53.163Z","phase":"Phase 1","brief_title":"Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT01059552","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" ERCC1 • HDAC1","pipe":" | ","alterations":" ERCC1 expression","tags":["ERCC1 • HDAC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Zolinza (vorinostat)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/16/2009","start_date":" 12/16/2009","primary_txt":" Primary completion: 07/22/2015","primary_completion_date":" 07/22/2015","study_txt":" Completion: 10/21/2019","study_completion_date":" 10/21/2019","last_update_posted":"2019-11-27"},{"id":"b6337e86-0dc4-4ad8-a712-c5f23b88b4b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00728000","created_at":"2021-01-19T08:28:53.247Z","updated_at":"2024-07-02T16:36:53.242Z","phase":"Phase 2","brief_title":"Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT00728000","lead_sponsor":"University of Cincinnati","biomarkers":" ERCC1 • ERCC2 • DCK","pipe":"","alterations":" ","tags":["ERCC1 • ERCC2 • DCK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gemcitabine • oxaliplatin"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2008","start_date":" 08/01/2008","primary_txt":" Primary completion: 08/01/2009","primary_completion_date":" 08/01/2009","study_txt":" Completion: 08/01/2010","study_completion_date":" 08/01/2010","last_update_posted":"2019-11-25"},{"id":"fd9d0f56-6ef5-4919-b94d-c1f0acdfa2c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00582634","created_at":"2021-01-18T02:08:39.259Z","updated_at":"2024-07-02T16:36:53.401Z","phase":"Phase 2","brief_title":"Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer","source_id_and_acronym":"NCT00582634","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" ERCC1","pipe":"","alterations":" ","tags":["ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 09/01/2004","start_date":" 09/01/2004","primary_txt":" Primary completion: 12/01/2007","primary_completion_date":" 12/01/2007","study_txt":" Completion: 12/01/2007","study_completion_date":" 12/01/2007","last_update_posted":"2019-11-19"},{"id":"9fd341ad-fb4f-4959-b5ab-ad5952779069","acronym":"","url":"https://clinicaltrials.gov/study/NCT01498289","created_at":"2021-01-18T06:17:01.945Z","updated_at":"2024-07-02T16:36:53.898Z","phase":"Phase 2","brief_title":"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT01498289","lead_sponsor":"Southwest Oncology Group","biomarkers":" HER-2 • ERCC1","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 expression","tags":["HER-2 • ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 213","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 09/19/2019","study_completion_date":" 09/19/2019","last_update_posted":"2019-11-07"},{"id":"c133b557-be46-42d3-9c3d-af32e8bdcbee","acronym":"","url":"https://clinicaltrials.gov/study/NCT01472601","created_at":"2021-01-18T06:08:26.884Z","updated_at":"2024-07-02T16:36:59.452Z","phase":"","brief_title":"A Prospective Study of Pharmacogenetic Factors and Gene Expression Profile","source_id_and_acronym":"NCT01472601","lead_sponsor":"Samsung Medical Center","biomarkers":" ERCC1 • GSTP1 • XRCC1","pipe":"","alterations":" ","tags":["ERCC1 • GSTP1 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Unknown status","enrollment":" Enrollment 2660","initiation":"Initiation: 05/24/2011","start_date":" 05/24/2011","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2019-05-20"},{"id":"665a24f0-30ae-47ae-bd4a-55761e74693b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02948075","created_at":"2021-01-18T14:28:35.503Z","updated_at":"2024-07-02T16:37:09.434Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy","source_id_and_acronym":"NCT02948075","lead_sponsor":"NewVac LLC","biomarkers":" BRCA1 • ERCC1 • CDH1","pipe":" | ","alterations":" BRCA1 expression • CDH1 expression • ERCC1 expression","tags":["BRCA1 • ERCC1 • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 expression • CDH1 expression • ERCC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • quisinostat (JNJ 26481585)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 06/16/2017","study_completion_date":" 06/16/2017","last_update_posted":"2018-06-27"},{"id":"6fdfc3eb-554f-464f-ba54-394093c8335c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02077998","created_at":"2021-01-18T09:34:43.518Z","updated_at":"2024-07-02T16:37:14.995Z","phase":"Phase 1","brief_title":"Oxaliplatin in Treating Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT02077998","lead_sponsor":"University of California, Davis","biomarkers":" ERCC1","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • EGFR positive","tags":["ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 05/01/2015","primary_completion_date":" 05/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2018-01-09"},{"id":"4c087aa4-7fbc-4077-85f7-c797c75edda2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00248495","created_at":"2021-01-18T00:50:30.979Z","updated_at":"2024-07-02T16:37:19.995Z","phase":"Phase 2","brief_title":"Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00248495","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" ERCC1","pipe":"","alterations":" ","tags":["ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 06/08/2005","start_date":" 06/08/2005","primary_txt":" Primary completion: 04/29/2011","primary_completion_date":" 04/29/2011","study_txt":" Completion: 04/05/2017","study_completion_date":" 04/05/2017","last_update_posted":"2017-07-12"}]